Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)

Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)

Background It is possible to induce immunomodulation in HER2-positive breast cancer (BC) by modifying the route of administration of trastuzumab.Methods In this multicenter randomized phase II trial, all enrolled patients (pts) with T2–T4d HER2-positive BC received 3 cycles of neoadjuvant treatment...

Full description

Bibliographic Details
Main Authors: Benedetta Pellegrino, Luisa Carbognin, Emilio Bria, Alberto Zambelli, Filippo Montemurro, Elena Fiorio, Claudio Zamagni, Nicoletta Campanini, Michele Tognetto, Gabriele Missale, Antonino Musolino, Stefania Gori, Giuseppe Maglietta, Chiara Tommasi, Olga Serra, Elisabetta Cretella, Massimo Ambroggi, Antonio Frassoldati, Giancarlo Bisagni, Chiara Casarini, Antonella Mura, Lorenzo Gianni, Renata Todeschini, Enrico Maria Silini
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/11/e007667.full

Internet

https://jitc.bmj.com/content/11/11/e007667.full

Similar Items